- Home
- BTOG vs APM Comparison
BTOG vs APM Comparison
Compare BTOG & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTOG
- APM
- Stock Information
- Founded
- BTOG 2018
- APM 2010
- Country
- BTOG Singapore
- APM United Kingdom
- Employees
- BTOG N/A
- APM N/A
- Industry
- BTOG Finance: Consumer Services
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- BTOG Finance
- APM Health Care
- Exchange
- BTOG Nasdaq
- APM Nasdaq
- Market Cap
- BTOG 28.8M
- APM 18.9M
- IPO Year
- BTOG 2019
- APM 2018
- Fundamental
- Price
- BTOG $0.33
- APM $1.85
- Analyst Decision
- BTOG
- APM
- Analyst Count
- BTOG 0
- APM 0
- Target Price
- BTOG N/A
- APM N/A
- AVG Volume (30 Days)
- BTOG 11.0M
- APM 20.3M
- Earning Date
- BTOG 01-01-0001
- APM 04-30-2025
- Dividend Yield
- BTOG N/A
- APM N/A
- EPS Growth
- BTOG N/A
- APM N/A
- EPS
- BTOG N/A
- APM N/A
- Revenue
- BTOG N/A
- APM N/A
- Revenue This Year
- BTOG N/A
- APM N/A
- Revenue Next Year
- BTOG N/A
- APM N/A
- P/E Ratio
- BTOG N/A
- APM N/A
- Revenue Growth
- BTOG N/A
- APM N/A
- 52 Week Low
- BTOG $0.12
- APM $0.46
- 52 Week High
- BTOG $3.09
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- BTOG 40.78
- APM 50.26
- Support Level
- BTOG $0.32
- APM $1.64
- Resistance Level
- BTOG $0.44
- APM $1.90
- Average True Range (ATR)
- BTOG 0.05
- APM 0.36
- MACD
- BTOG -0.02
- APM -0.06
- Stochastic Oscillator
- BTOG 6.22
- APM 18.38
About BTOG Bit Origin Limited
Bit Origin Ltd is seeking opportunities in deploying new technologies, crypto asset mining and blockchain technologies in Singapore. The company has focused on building the Bitcoin mining ecosystem through incubations, strategic investments, and acquisitions.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.